二仙汤加减治疗卵巢功能早衰疗效的系统评价

朱梦蝶; 崔彬; 林文君; 窦丹; 王清

doi:10.14009/j.issn.1672-2124.2022.02.024

您当前的位置：

首页 >

文章列表页 >

二仙汤加减治疗卵巢功能早衰疗效的系统评价

用药评价 | 更新时间：2022-10-08

- 二仙汤加减治疗卵巢功能早衰疗效的系统评价
- Systematical Review of Modified Erxian Decoction in the Treatment of Premature Ovarian Failure
- 中国医院用药评价与分析 2022年22卷第2期页码：224-231
- 作者机构：
  
  1. 北京中医药大学中日友好临床医学院
  2. 中日友好医院中医妇科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.02.024
  中图分类号： R271.9
- 纸质出版日期：2022，
扫描看全文
朱梦蝶, 崔彬, 林文君, 等. 二仙汤加减治疗卵巢功能早衰疗效的系统评价[J]. 中国医院用药评价与分析, 2022,22(2):224-231.

ZHU Mengdie, CUI Bin, LIN Wenjun, et al. Systematical Review of Modified Erxian Decoction in the Treatment of Premature Ovarian Failure[J]. 2022,22(2):224-231.
朱梦蝶, 崔彬, 林文君, 等. 二仙汤加减治疗卵巢功能早衰疗效的系统评价[J]. 中国医院用药评价与分析, 2022,22(2):224-231. DOI： 10.14009/j.issn.1672-2124.2022.02.024.

ZHU Mengdie, CUI Bin, LIN Wenjun, et al. Systematical Review of Modified Erxian Decoction in the Treatment of Premature Ovarian Failure[J]. 2022,22(2):224-231. DOI： 10.14009/j.issn.1672-2124.2022.02.024.

摘要

目的：系统评价二仙汤加减治疗卵巢功能早衰的临床疗效，以期为临床用药提供循证参考。方法：检索中国知网、万方数据库、维普数据库、中国生物医学文献数据库、PubMed、Embase和the Cochrane Library

收集二仙汤加减治疗卵巢功能早衰的随机对照研究（包括二仙汤加减联合西药与西药比较、二仙汤加减与西药比较）

检索时限为各数据库建库至2021年4月，根据相关标准筛选文献、评价质量和提取数据，使用RevMan 5.3软件进行Meta分析。结果：二仙汤加减联合西药治疗卵巢功能早衰最终纳入8篇文献，二仙汤加减治疗卵巢功能早衰最终纳入9篇文献，共1 281例患者。Meta分析结果显示，与单纯西药治疗比较，二仙汤加减治疗卵巢功能早衰可明显提高总有效率（二仙汤加减联合西药：OR=3.18

95%CI=2.08～4.86

0.000 01;二仙汤加减：OR=3.55

95%CI=2.03～6.22

0.000 01）

明显提高E

水平（二仙汤加减联合西药：MD=7.55

95%CI=6.77～8.33

0.000 01;二仙汤加减：MD=9.38

95%CI=5.14～13.63

0.000 1）、CD4

水平（二仙汤加减联合西药：MD=7.05

95%CI=5.60～8.49

0.000 1;二仙汤加减：MD=4.72

95%CI=3.21～6.24

0.000 01）和CD4

/CD8

水平（二仙汤加减联合西药：MD=0.49

95%CI=0.45～0.52

0.000 01;二仙汤加减：MD=0.52

95%CI=0.41～0.62

0.000 01）

明显降低FSH水平（二仙汤加减联合西药：MD=-10.85

95%CI=-15.59～-6.11

0.000 01;二仙汤加减：MD=-4.49

95%CI=-5.68～-3.31

0.000 01）、LH水平（二仙汤加减联合西药：MD=-6.60

95%CI=-7.12～-6.09

0.000 01;二仙汤加减：MD=-5.95

95%CI=-7.23～-4.67

0.000 01）和不良反应发生率（OR=0.29

95%CI=0.11～0.76

P=0.01）

上述差异均有统计学意义。在降低CD8

水平方面，二仙汤加减联合西药治疗明显优于单纯西药治疗，差异有统计学意义（MD=-4.70

95%CI=-5.38～-4.01

0.000 01）。结论：二仙汤加减或二仙汤加减联合西药治疗卵巢功能早衰的疗效优于单纯西药治疗，但仍需更多大样本、多中心、高质量和科学规范的随机对照试验进一步验证。

Abstract

OBJECTIVE: To systematically evaluate the clinical efficacy of modified Erxian decoction in the treatment of premature ovarian failure

so as to provide evidence-based reference for clinical drug use. METHODS: CNKI

Wanfang Data

VIP database

CBM

PubMed

Embase and the Cochrane Library were retrieved to collect the randomized controlled trial of modified Erxian decoction in the treatment of premature ovarian failure（comparison of modified Erxian decoction combined with western medicine and western medicine

comparison of modified Erxian decoction and western medicine）. The retrieval time was from the establishment of the database to Apr. 2021. Literature was screened

quality was evaluated and data was extracted according to relevant criteria. Meta-analysis was performed by using RevMan 5.3 software. RESULTS: Eight literature were enrolled in the treatment of premature ovarian failure by modified Erxian decoction combined with western medicine

and 9 literature were enrolled in the treatment of premature ovarian failure by modified Erxian decoction

with a total of 1 281 patients. The results of Meta-analysis showed that compared with the simple western medicine treatment

the modified Erxian decoction in the treatment of premature ovarian failure can significantly improve the total effective rate（modified Erxian decoction combined with western medicine: OR=3.18

95%CI=2.08-4.86

0.000 01; modified Erxian decoction: OR=3.55

95%CI=2.03-6.22

0.000 01）

significantly increase the E

level（modified Erxian decoction combined with western medicine: MD=7.55

95%CI=6.77-8.33

0.000 01; modified Erxian decoction: MD=9.38

95%CI=5.14-13.63

0.000 1）

CD4

level（modified Erxian Decoction combined with western medicine: MD=7.05

95%CI=5.60-8.49

0.000 1; modified Erxian decoction: MD=4.72

95%CI=3.21-6.24

0.000 01） and CD4

/CD8

level（modified Erxian decoction combined with western medicine: MD=0.49

95%CI=0.45-0.52

0.000 01; modified Erxian decoction: MD=0.52

95%CI=0.41-0.62

0.000 01）

significantly decrease the FSH level（modified Erxian decoction combined with western medicine: MD=-10.85

95%CI=-15.59--6.11

0.000 01; modified Erxian decoction: MD=-4.49

95%CI=-5.68--3.31

0.000 01）

LH level（modified Erxian decoction combined with western medicine: MD=-6.60

95%CI=-7.12--6.09

0.000 01; modified Erxian decoction: MD=-5.95

95%CI=-7.23--4.67

0.000 01） and incidence of adverse drug reactions（OR=0.29

95%CI=0.11-0.76

P=0.01）

the differences were statistically significant. In terms of lowering CD8

level

modified Erxian decoction combined with western medicine was significantly better than western medicine alone

with statistically significant difference（MD=-4.70

95%CI=-5.38--4.01

0.000 01）. CONCLUSIONS: The efficacy of modified Erxian decoction or modified Erxian decoction combined with western medicine in the treatment of premature ovarian failure is better than that of western medicine alone

yet more large-sample

multi-center

high-quality and scientifically standardized randomized controlled trials are still needed for further verification.

关键词

二仙汤加减西药卵巢功能早衰Meta分析

Keywords

Modified Erxian decoctionWestern medicinePremature ovarian failureMeta-analysis

references

查看原文

浏览量

134

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

回生口服液对非小细胞肺癌患者凝血功能、疗效及安全性影响的系统评价

丹田降脂丸联合他汀类药物治疗高脂血症疗效与安全性的系统评价

良附丸中药配方颗粒治疗胃脘痛临床疗效和安全性的系统评价

润燥止痒胶囊联合抗组胺药治疗慢性荨麻疹的系统评价

基于Meta分析的替格瑞洛联合瑞舒伐他汀治疗不稳定型心绞痛的疗效和安全性评价